Key Highlights

● TWST shares closed at $155.65 on October 7, 2026, down 6.78% on the day.

● No Earnings release, guidance revision, downgrade, partnership, regulatory development, or management change was tied to the session.

● Twist's valuation rests heavily on the promise of future expansion, making it vulnerable to a rise in the discount rate applied to distant cash flows.

● The Russell 2000 dropped roughly 1.31%, the hallmark of a rate-shock selloff hitting smaller, more speculative companies hardest.

Twist Bioscience (NASDAQ:TWST), the synthetic-biology and DNA-manufacturing company, closed the most recently completed US Trading session on Wednesday, October 7, 2026, at $155.65, down 6.78% on the day. The decline placed Twist among the session's growth-stock casualties, and the move lines up with the dominant macro theme of the day rather than any confirmed, company-specific event.

A High-Multiple Growth Story Facing Higher Rates

No verified news from Twist accompanied the drop. Twist fits the profile of a stock that is especially vulnerable to a Yield shock. As a high-growth, innovation-driven company whose valuation rests heavily on the promise of future expansion rather than current profitability, it carries the long-duration characteristics that the market punishes when rates climb.

A Broad Repricing of Growth Valuations

On October 7, that repricing was severe: the 10-year Treasury Yield pushed to roughly 5.35%, its highest since 2002. The clearest signal came from the small-cap Russell 2000, which dropped roughly 1.31%, making it the weakest major index. That underperformance by smaller, more speculative, and more rate-sensitive companies is the hallmark of a rate-shock selloff, and higher-multiple growth names were caught in the same current.

Macro-Driven Volatility, Not a Fundamental Shift

There is no confirmed evidence that anything changed inside Twist Bioscience's Business on October 7. For a high-multiple innovator, macro-driven Volatility of this kind comes with the territory.